Yahoo · Nov 19, 2026
GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software
GEHC secures FDA clearance for AI-powered feeding tube detection software, expanding bedside X-ray capabilities for adult and pediatric patients.

NASDAQ · ISRG
Healthcare · Medical - Instruments & Supplies
$407.24
Down-$13.71 (-3.26%)
Updated Nov 20, 2026, 2:12 AM
SID Score
4.7/10
Composite research score
Smart Money
40/100
Neutral
Price performance · ISRG
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
ISRG closed at $407.24 after 21 trading sessions, down 8.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $421.45 | $425.105 | $404.85 | $407.24 | 2.09M |
| Nov 18, 2026 | $430.20 | $437.325 | $420.84 | $420.95 | 2.22M |
| Nov 17, 2026 | $437.33 | $441.285 | $428.71 | $430.53 | 2.53M |
| Nov 16, 2026 | $444.38 | $446.20 | $436.71 | $437.75 | 1.82M |
| Nov 13, 2026 | $443.69 | $448.85 | $441.00 | $443.59 | 1.6M |
| Nov 12, 2026 | $449.00 | $451.26 | $438.44 | $439.89 | 1.79M |
| Nov 11, 2026 | $446.00 | $451.00 | $443.24 | $449.53 | 1.75M |
| Nov 10, 2026 | $460.48 | $460.48 | $444.16 | $450.04 | 1.66M |
| Nov 9, 2026 | $456.66 | $463.00 | $454.04 | $460.56 | 2.16M |
| Nov 6, 2026 | $457.00 | $463.25 | $450.5125 | $452.80 | 2.15M |
| Nov 5, 2026 | $482.88 | $485.17 | $461.19 | $468.52 | 4.7M |
| Nov 4, 2026 | $458.99 | $485.85 | $453.69 | $482.10 | 4.83M |
| Nov 3, 2026 | $436.65 | $443.58 | $434.05 | $440.75 | 1.74M |
| Nov 2, 2026 | $439.79 | $446.455 | $436.04 | $436.87 | 3.81M |
| Oct 30, 2026 | $453.60 | $453.60 | $431.1949 | $432.01 | 3.48M |
| Oct 29, 2026 | $447.85 | $450.40 | $443.475 | $448.76 | 1.89M |
| Oct 28, 2026 | $441.425 | $449.97 | $437.5101 | $444.18 | 1.85M |
| Oct 27, 2026 | $451.63 | $451.63 | $443.8501 | $445.88 | 1.7M |
| Oct 26, 2026 | $451.93 | $458.88 | $447.61 | $451.63 | 3.07M |
| Oct 23, 2026 | $443.65 | $458.45 | $442.56 | $452.29 | 3.01M |
| Oct 22, 2026 | $430.745 | $444.15 | $427.47 | $443.85 | 2.78M |
The latest Smart Investors Daily articles mentioning ISRG.
Company
Market Activity
Research & News
ISRG research
Company profile and research snapshot.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 18, 2026 | BTIG | Buy | — |
| Oct 21, 2026 | Evercore ISI Group | In-Line | — |
| Oct 21, 2026 | Barclays | Overweight | — |
| Oct 21, 2026 | TD Cowen | Buy | — |
| Oct 21, 2026 | Wells Fargo | Overweight | — |
No generated briefing is available yet.
Yahoo · Nov 19, 2026
GEHC secures FDA clearance for AI-powered feeding tube detection software, expanding bedside X-ray capabilities for adult and pediatric patients.
Yahoo · Nov 19, 2026
Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Nov 19, 2026
NPCE's RNS adoption, new indications and reimbursement gains offer growth potential, but weak sales execution and regulatory hurdles pose near-term risks.
Yahoo · Nov 19, 2026
PHG launches cloud-based Skylight Device Manager to optimize ultrasound fleet management, boost equipment utilization and streamline healthcare operations.
Interpretive context generated from the platform’s current data sources.
Intuitive Surgical, Inc. shares closed at $420.95, declining 0.85% in the most recent session, per SID market data. The stock has exhibited mixed momentum across timeframes, posting a modest 1-month decline of 0.61% while gaining 8.25% over the trailing three months. On a 12-month basis, however, ISRG has retreated 21.26%, reflecting broader pressure on high-multiple healthcare names. The stock currently trades just above its 50-day moving average of $420.62 but remains below its 200-day moving average of $429.00, indicating a neutral-to-bearish technical posture. The 14-day relative strength index stands at 45.3, placing the stock in neutral territory without overbought or oversold signals. ISRG carries a beta of 1.686, per Massive/Polygon data, indicating significantly higher volatility relative to the broader market. Average daily trading volume stands at approximately 2.26 million shares, supporting adequate liquidity for institutional participants.
Intuitive Surgical commands a market capitalization of approximately $195.5 billion, reflecting its dominant position in robotic-assisted surgery, per SID market data. The company's trailing price-to-earnings ratio stands at 71.05, well above the broader healthcare sector average, underscoring the premium valuation investors assign to its growth trajectory and competitive moat. The PEG ratio of 13.30 suggests that even when adjusting for expected earnings growth, the stock trades at an elevated multiple relative to typical growth benchmarks. According to SEC filings, the price-to-book ratio registers at 11.53, further highlighting the significant premium over tangible asset value. Intuitive Surgical pays no dividend, consistent with its reinvestment-focused capital allocation strategy. As a healthcare sector constituent with no yield component, the stock's investment case rests entirely on capital appreciation driven by procedure volume growth, system placements, and recurring instrument and accessory revenue streams.
Intuitive Surgical's composite smart money score stands at 40 out of 100, registering a neutral signal, per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, reflecting strong conviction among large asset managers and mutual funds in the company's long-term positioning. In contrast, the insider sentiment component scores just 5.3 out of 25, weighed down by a notable imbalance in recent insider transactions. According to SEC Form 4 filings, there have been 20 insider trades over the past 90 days, comprising 6 purchases and 14 sales, indicating that company insiders have been net sellers during this period. Dark pool activity scores 8.5 out of 25, suggesting moderate but not elevated institutional block trading. Congressional trading activity is minimal, registering only 0.8 out of 25 per 13F institutional filings. The divergence between strong institutional ownership and insider selling patterns presents a nuanced signal, with institutional holders maintaining positions while insiders reduce exposure at current valuation levels.
Intuitive Surgical has demonstrated a consistent pattern of exceeding analyst expectations across its three most recent reported quarters, according to company earnings reports. In the most recent quarter, the company delivered earnings per share of $3.00 against a consensus estimate of $2.54, representing an 18.1% upside surprise. The prior quarter showed EPS of $2.80 versus the $2.41 estimate, a $0.39 positive surprise, while the quarter before that produced EPS of $2.50 compared to the $1.92 consensus, delivering the largest beat of $0.58 or 30.2% above expectations. Analyst estimates for the upcoming quarter project EPS of $2.41, per consensus data. The sequential acceleration in absolute earnings from $2.50 to $2.80 to $3.00 reflects robust underlying business momentum driven by increasing da Vinci system utilization and growing procedure volumes. The consistent pattern of outperformance suggests that analyst models may continue to underestimate the company's earnings power.
Wall Street consensus on Intuitive Surgical remains predominantly bullish, with four of the five most recent analyst actions carrying positive ratings, per Wall Street analyst reports. BTIG reiterated a Buy rating on November 18, 2026, maintaining its constructive stance on the stock. Following the company's earnings release on October 21, 2026, multiple firms reaffirmed their positive outlooks: Barclays maintained an Overweight rating, Wells Fargo reiterated Overweight, and TD Cowen held its Buy recommendation. Evercore ISI Group maintained its In-Line rating, representing the sole neutral voice among recent coverage updates, per SID consensus data. Notably, none of the five most recent analyst actions involved a rating change, with each firm reiterating its prior assessment, suggesting stable institutional conviction despite the stock's 21.26% year-over-year decline. The absence of any downgrades following earnings results indicates that the company's fundamental performance continues to meet or exceed the investment theses underpinning these bullish recommendations from major sell-side firms.


The latest Smart Investors Daily articles mentioning ISRG.